High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy

Journal of Clinical Oncology

Volumn 13, Issue 3, 1995, Pages 596-602

  Demirer, Taner ^a   Weaver, Charles H ^b   Buckner, C Dean ^b   Petersen, Finn B ^b   Bensinger, William I ^b   Sanders, Jean ^b   Clift, Reginald A ^b   Lilleby, Kathy ^b   Anasetti, Claudio ^b   Martin, Paul ^b   Storb, Rainer ^b   Chauncey, Thomas ^b   Doney, Kristine ^b   Sullivan, Keith ^b   Appelbaum, Frederick R ^b  

^a FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IDIOPATHIC DISEASE; INTRATHECAL DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0028939820     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.3.596     Document Type: Article

References (33)

1. Appelbaum FR, Sullivan KM, Buckner CD, et al: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340-1347, 1987
2. Phillips GL, Wolff SN, Herzig RH, et al: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086-2092, 1989
3. Petersen FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 8:638-647, 1990
4. Appelbaum FR, Thomas ED: Bone marrow transplantation for malignant lymphoma. Eur J Cancer Clin Oncol 23:263-266, 1987
5. Pecego R, Hill R, Appelbaum FR, et al: Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 42:515-517, 1986
6. Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347-1353, 1983
7. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382-1388, 1987
8. Van der Jagt RHC, Appelbaum FR, Petersen FB, et al: Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplantation 8:211-215, 1991
9. Jagannath S, Dicke KA, Armitage JO, et al: High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104:163-168, 1986
10. Philip T, Dumont J, Teillet F, et al: High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br J Cancer 53:737-742, 1986
11. Carella AM, Congiu AM, Gaozza E, et al: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 6:1411-1416, 1988
12. Gribben JG, Linch DC, Singer CRJ, et al: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340-344, 1989
13. Jagannath S, Armitage JO, Dicke KA, et al: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179-185, 1989
14. Reece DE, Barnett MJ, Connors JM, et al: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871-1879, 1991
15. Ahmed T, Ciavarella D, Feldman E, et al: High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Leukemia 3:19-22, 1989
16. Weaver CH, Appelbaum FR, Buckner CD, et al: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11:1329-1335, 1993
17. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
18. Lukes RJ, Butler JJ: The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063-1681, 1966
19. Storb R, Buckner CD, Thomas ED, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735, 1986
20. Doney KC, Storb R, Thomas ED, et al: Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing anti-thymocyte globulin and corticosteroids. Am J Hematol 11:1-8, 1981
21. Remlinger K, Martin PJ, Sullivan KM, et al: Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Hum Immunol 9:21-35, 1984
22. Sullivan KM, Storb R, Sanders JE, et al: Alternating-day cyclosporine, and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555-561, 1988
23. Hansen JA, Choo SY, Michelson E, et al: The HLA system in clinical marrow transplantation. Hematol Oncol Clin North Am 4:507-515, 1990
24. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
25. Clark JG, Hansen JA, Hertz MI, et al: Idiopathic pneumonia syndrome following bone marrow transplantation. Am Rev Respir Dis 147:1601-1606, 1993
26. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 4:42-93, 1986
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Wheeler C, Antin JH, Churchill WH, et al: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 8:648-656, 1990
29. Phillips GL, Reece DE, Wolff SN, et al: Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 7:1039-1045, 1989
30. Zander AR, Vellekoop L, Spitzer G, et al: Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Cancer Treat Rep 65:377-381, 1981
31. Vellekoop L, Dicke K, Zander AR, et al: Repeated high-dose cyclophosphamide, BCNU, and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission. Eur J Cancer Clin Oncol 20:593-599, 1984
32. Vellekoop L, Jagannath S, Spitzer G, et al: High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse. Am J Clin Oncol 9:307-310, 1986
33. Zander AR, Jagannath S, Spitzer G, et al: High-dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 59:1083-1086, 1987